Current status of anti-vascular endothelial growth factor therapy in Europe

Wolf, Sebastian (2008). Current status of anti-vascular endothelial growth factor therapy in Europe. Japanese journal of ophthalmology, 52(6), pp. 433-9. Tokyo: Springer Japan 10.1007/s10384-008-0580-4

[img]
Preview
Text
10384_2008_Article_580.pdf - Published Version
Available under License Publisher holds Copyright.

Download (298kB) | Preview

Vascular endothelial growth factor (VEGF) is an important modulator of angiogenesis, and has been implicated in the pathology of a number of conditions, including age-related macular degeneration (AMD), diabetic retinopathy, and cancer. AMD is a progressive disease of the macula and the third major cause of blindness worldwide. If not treated appropriately, AMD can progress rapidly, causing legal blindness within months of the second eye becoming affected. Until recently, the treatment options for AMD have been limited, with photodynamic therapy (PDT) the mainstay treatment. Although PDT is effective at slowing disease progression, it rarely results in improved vision. Pegaptanib and ranibizumab are both anti-VEGF therapies licensed for the treatment of neovascular AMD in Europe; however, these drugs are not yet available in Japan. This article reviews the available clinical data on anti-VEGF therapies for the treatment of neovascular AMD in Europe, and considers the future of this exciting therapy.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Wolf, Sebastian

ISSN:

0021-5155

ISBN:

19089562

Publisher:

Springer Japan

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:05

Last Modified:

26 Jun 2018 15:01

Publisher DOI:

10.1007/s10384-008-0580-4

PubMed ID:

19089562

Web of Science ID:

000261789400001

BORIS DOI:

10.7892/boris.28218

URI:

https://boris.unibe.ch/id/eprint/28218 (FactScience: 118866)

Actions (login required)

Edit item Edit item
Provide Feedback